n-methyl-3,4-methylenedioxyamphetamine has been researched along with Child Development Deviations in 3 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kisely, S | 1 |
| Connor, M | 1 |
| Somogyi, AA | 1 |
| Siskind, D | 1 |
| Singer, LT | 2 |
| Moore, DG | 2 |
| Min, MO | 2 |
| Goodwin, J | 2 |
| Turner, JJ | 2 |
| Fulton, S | 2 |
| Parrott, AC | 2 |
1 review available for n-methyl-3,4-methylenedioxyamphetamine and Child Development Deviations
| Article | Year |
|---|---|
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.
Topics: Adult; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Developmental Disabilities; Humans; N | 2023 |
2 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Child Development Deviations
| Article | Year |
|---|---|
Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK.
Topics: Adult; Age Factors; Child Development; Developmental Disabilities; Female; Hallucinogens; Humans; In | 2015 |
One-year outcomes of prenatal exposure to MDMA and other recreational drugs.
Topics: Cognition; Developmental Disabilities; Dose-Response Relationship, Drug; Female; Hallucinogens; Huma | 2012 |